Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Ocular Therapeutix, Inc (OCUL)

A forensic read on Ocular Therapeutix, Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution

Forensic grade

Grey Zone

Financial health

3.5

Distress distance

Forensic signals

-54.9%

ROE

-18.5%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Ocular Therapeutix, Inc earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 3.5, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+47.9%/yr

FY2023–FY2025

Share-count dilution. Diluted share count changed +119% over the last 2 years to FY2025 (+47.9%/yr). The count is growing — 85.6M shares in FY2023, 187.2M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~47.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~54%.

183d

FY2024→FY2025

Inventory days. Days inventory outstanding moved from 173 to 183 FY2024→FY2025 (against cost of goods sold; inventory +17% vs +17% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.

83% of rev

FY2025

Stock-based comp load. Stock-based compensation ran 83% of revenue in FY2025 — about $0.23 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 47.9% a year across FY2023–FY2025, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.

Key fundamentals

Latest Revenue$52.0M

Revenue Growth YoY-18.5%

Revenue CAGR (2yr)-5.7%

Net Margin-511.9%

Free Cash Flow-$216.9M

Return on Equity-54.9%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Ocular Therapeutix, Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.